Emilio Sanseviero

Emilio Sanseviero

Auto-generated profile, based on publicly available information

Emilio Sanseviero

Oncology R&D, ICC AstraZeneca Gaithersburg, USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 February 2021 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
FVFilippo Veglia
Filippo Veglia
AHAyumi Hashimoto
Ayumi Hashimoto
HDHarsh Dweep
Harsh Dweep
ESEmilio Sanseviero
Emilio Sanseviero
ALAlessandra De Leo
Alessandra De Leo
DGDmitry Gabrilovich
Dmitry Gabrilovich
In this study, using single-cell RNA-seq, cell mass spectrometry, flow cytometry, and functional analysis, we characterized the heterogeneity of polymorphonuclear neutrophils (PMNs) in cancer. We describe three populations of PMNs in tumor-bearing mice: classical PMNs, polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs), and activated PMN-MDSCs with potent immune suppressive activity. In spleens of mice, PMN-MDSCs gradually replaced PMNs during tumor progression. Activated PMN-MDSCs were found only in tumors, where they were present at the very early stages of the disease. These populations of PMNs in mice could be separated based on the expression of CD14. In peripheral blood of cancer patients, we identified two distinct populations of PMNs with characteristics of classical PMNs and PMN-MDSCs. The gene signature of tumor PMN-MDSCs was similar to that in mouse activated PMN-MDSCs and was closely associated with negative clinical outcome in cancer patients. Thus, we provide evidence that PMN-MDSCs are a distinct population of PMNs with unique features and potential for selective targeting opportunities.

15 November 2015 in Cancer Research
Verified
Journal Article
Open access
PDF file
APAndrea Ponzetta
Andrea Ponzetta
GBGiorgia Benigni
Giorgia Benigni
FAFabrizio Antonangeli
Fabrizio Antonangeli
GSGiuseppe Sciume
Giuseppe Sciume
ESEmilio Sanseviero
Emilio Sanseviero
GBGiovanni Bernardini
Giovanni Bernardini
Natural killer (NK) cells are key innate immune effectors against multiple myeloma, their activity declining in multiple myeloma patients with disease progression. To identify the mechanisms underlying NK cell functional impairment, we characterized the distribution of functionally distinct NK cell subsets in the bone marrow of multiple myeloma-bearing mice. Herein we report that the number of KLRG1− NK cells endowed with potent effector function rapidly and selectively decreases in bone marrow during multiple myeloma growth, this correlating with decreased bone marrow NK cell degranulation in vivo. Altered NK cell subset distribution was dependent on skewed chemokine/chemokine receptor axes in the multiple myeloma microenvironment, with rapid downmodulation of the chemokine receptor CXCR3 on NK cells, increased CXCL9 and CXCL10, and decreased CXCL12 expression in bone marrow. Similar alterations in chemokine receptor/chemokine axes were observed in patients with multiple myeloma. Adoptive transfer experiments demonstrated that KLRG1− NK cell migration to the bone marrow was more efficient in healthy than multiple myeloma–bearing mice. Furthermore, bone marrow localization of transferred CXCR3-deficient NK cells with respect to wild type was enhanced in healthy and multiple myeloma-bearing mice, suggesting that CXCR3 restrains bone marrow NK cell trafficking. Our results indicate that multiple myeloma–promoted CXCR3 ligand upregulation together with CXCL12 downmodulation act as exit signals driving effector NK cells outside the bone marrow, thus weakening the antitumor immune response at the primary site of tumor growth. Cancer Res; 75(22); 4766–77. ©2015 AACR.

1 March 2017 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
GBGiorgia Benigni
Giorgia Benigni
PDPetya A. Dimitrova
Petya A. Dimitrova
FAFabrizio Antonangeli
Fabrizio Antonangeli
ESEmilio Sanseviero
Emilio Sanseviero
VMViktoriya Milanova
Viktoriya Milanova
GBGiovanni Bernardini
Giovanni Bernardini
Several immune cell populations are involved in cartilage damage, bone erosion, and resorption processes during osteoarthritis. The purpose of this study was to investigate the role of NK cells in the pathogenesis of experimental osteoarthritis and whether and how neutrophils can regulate their synovial localization in the disease. Experimental osteoarthritis was elicited by intra-articular injection of collagenase in wild type and Cxcr3−/− 8-wk old mice. To follow osteoarthritis progression, cartilage damage, synovial thickening, and osteophyte formation were measured histologically. To characterize the inflammatory cells involved in osteoarthritis, synovial fluid was collected early after disease induction, and the cellular and cytokine content were quantified by flow cytometry and ELISA, respectively. We found that NK cells and neutrophils are among the first cells that accumulate in the synovium during osteoarthritis, both exerting a pathogenic role. Moreover, we uncovered a crucial role of the CXCL10/CXCR3 axis, with CXCL10 increasing in synovial fluids after injury and Cxcr3−/− mice being protected from disease development. Finally, in vivo depletion experiments showed that neutrophils are involved in an NK cell increase in the synovium, possibly by expressing CXCL10 in inflamed joints. Thus, neutrophils and NK cells act as important disease-promoting immune cells in experimental osteoarthritis and their functional interaction is promoted by the CXCL10/CXCR3 axis.

22 December 2022 in Cancer Immunology Research
Verified
Journal Article
Closed access
PDF file
SFShuyu Fu
Shuyu Fu
HDHui Deng
Hui Deng
IBIRENE BERTOLINI
IRENE BERTOLINI
MPMichela Perego
Michela Perego
ECEric S. Chen
Eric S. Chen
DGDmitry Gabrilovich
Dmitry Gabrilovich
Pathologically activated neutrophils (PMN) with immunosuppressive activity, which are termed myeloid-derived suppressor cells (PMN-MDSC), play a critical role in regulating tumor progression. These cells have been implicated in promoting tumor metastases by contributing to premetastatic niche formation. This effect was facilitated by enhanced spontaneous migration of PMN from bone marrow to the premetastatic niches during the early-stage of cancer development. The molecular mechanisms underpinning this phenomenon remained unclear. In this study, we found that syntaphilin (SNPH), a cytoskeletal protein previously known for anchoring mitochondria to the microtubule in neurons and tumor cells, could regulate migration of PMN. Expression of SNPH was decreased in PMN from tumor-bearing mice and patients with cancer as compared with PMN from tumor-free mice and healthy donors, respectively. In Snph-knockout (SNPH-KO) mice, spontaneous migration of PMN was increased and the mice showed increased metastasis. Mechanistically, in SNPH-KO mice, the speed and distance travelled by mitochondria in PMN was increased, rates of oxidative phosphorylation and glycolysis were elevated, and generation of adenosine was increased. Thus, our study reveals a molecular mechanism regulating increased migratory activity of PMN during cancer progression and suggests a novel therapeutic targeting opportunity.


22 July 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
STSehmus Tohumeken
Sehmus Tohumeken
AMAli Mostafa
Ali Mostafa
RBRashmi Binjawadagi
Rashmi Binjawadagi
MMMimi Mai
Mimi Mai
APAna Paucarmayta
Ana Paucarmayta
DGDmitry Gabrilovich
Dmitry Gabrilovich
Antibody–drug conjugates (ADCs) have emerged as a transformative class of cancer therapeutics with important challenges still to be addressed. Combination of ADC with immunotherapy is a promising strategy but mechanisms and effective application remain to be determined. We evaluated ADC combinations with T cell engagers (TCEs) and checkpoint inhibitors (CPI). ADC–TCE combinations produced robust antitumor activity independent of antigen and payload and persisted despite ADC-related T cell loss. Efficacy was dominated by a direct effect of ADC on tumor cells. ADCs induced autophagy that upregulated TNF receptors (TNFRs) and mannose-6-phosphate receptors (M6PR). When ADCs were combined with TCEs TNFα released by T cells was primarily responsible for potent antitumor effect of combination. In contrast, M6PR was dispensable for ADC–TCE activity but critical for combinations with CPI expanded antigen-specific T cells via enhanced granzyme B uptake. These data reveal a unifying, target- and payload-agnostic mechanism enabling rational ADC–immunotherapy combinations. Significance: This is first evidence that ADC-induced tumor cell autophagy via up-regulation of TNFR and M6PR could be responsible for potent antitumor effect of combination of ADC with TCE. TCEs exploit a TNFα–TNFR axis, whereas antigen-specific T cells leverage granzyme B–M6PR uptake. This mechanistic framework explains broad ADC–TCE synergy and guides rational selection of ADC–immunotherapy combinations beyond checkpoint blockade.